About
Genetix Biotherapeutics is a privately-held, commercial-stage biotechnology company dedicated to delivering potentially curative genetic therapies for patients living with severe rare diseases.The company focuses on developing and commercializing one-time administered gene therapies that directly treat the underlying genetic cause of the disease. They currently have FDA-approved treatments for:Sickle Cell Disease (Product: LYFGENIA)$\beta$-thalassemia (Product: ZYNTEGLO)Cerebral Adrenoleukodystrophy (CALD) (Product: SKYSONA)With a foundation of over 30 years of genetic therapy innovation, Genetix Biotherapeutics is committed to scaling patient access, commercial execution, and improving the overall treatment experience for patients and healthcare providers.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 20 investors are based in Somerville, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- Somerville, US
Contact Information
Find more investors like Genetix
Search Investors